Trastuzumab, a humanized monoclonal antibody against the extracellular domain of HER2, in combination with chemotherapy, prolongs survival of early and metastatic HER2-positive breast cancer patients [5], [6], [7]. This evidence concerns the gene ERBB2 and breast carcinoma.